Engineered Interleukin-1 Receptor Antagonist For Osteoarthritis
Filed in archive Drugs, Vaccines and Therapeutics , Genomics, Proteomics and Bioinformatics by ruth on October 16, 2006

By experimenting with composition, molecular weight and concentration of various ELPs, researchers have come up with a modified Interleukin-1 receptor antagonist which, when tested on rats, has a 25-fold longer half-life in the joint than a similar soluble protein.
The results even suggest that the fusion protein might do better in an arthritic joint as the same inflammatory enzymes that destroy joint Collagen
also remove ELP from the original drug protein, thereby restoring its activity."With this advance, we believe treatments could go from twice a week to perhaps twice a month, and that would be a huge clinical gain."
Read the full feature report from EurekAlert.
Permalink: Engineered Interleukin-1 Receptor Antagonist For Osteoarthritis
Tags:
arthritis autoimmune+disease osteoarthritis proteomics biotech interleukin+receptor receptor+antagon
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/39299







